Latest news with #MolecuLight
Associated Press
3 days ago
- Health
- Associated Press
Landmark Study Affirms MolecuLight's Efficacy in Real-Time Bacterial Detection for Improved Wound Management
PITTSBURGH, June 26, 2025 /PRNewswire/ - MolecuLight Corp., a global pioneer in point-of-care fluorescence imaging for wound care, proudly announces the publication of a landmark systematic review by researchers at Trinity College Dublin and the Royal College of Surgeons in Ireland (RCSI). Titled 'The Clinical Utility of Autofluorescence Imaging for Bacterial Detection in Wounds', this review is the first to systematically compile data from 17 studies on fluorescence imaging.1 It conclusively establishes the crucial role of MolecuLight's technology in enhancing wound assessment by equipping clinicians with real-time, actionable information to effectively detect elevated bacterial burden, fundamentally transforming wound management. 'This new publication is a crucial step forward for MolecuLight. It provides a comprehensive review of existing evidence, further underscoring the essential role of MolecuLight's fluorescence imaging in elevating wound care,' said Anil Amlani, CEO of MolecuLight. 'Bacterial bioburden leads to infections and is a critical factor inhibiting wound healing, and this paper clearly articulates how our technology empowers clinicians to not only identify the presence and location of bacteria but also to guide targeted interventions. Ultimately, this leads to faster and more effective healing for patients, further strengthening the growing body of evidence supporting our technology's profound impact.' 'As a co-author of this systematic review and an academic and researcher who utilized MolecuLight's technology in practice, I can attest to the profound impact it has on clinicians' ability to manage complex wounds,' said study author Rosemarie Derwin, PhD, MSc, PG Dip, BNS, RGN, RNT, experienced nurse, educator, and researcher at the School of Nursing and Midwifery, Trinity College Dublin. 'The real-time visualization of bacteria provides immediate practical information that guides treatment decisions, leading to more effective care plans and ultimately, better outcomes for patients. This study affirms what many of us have seen clinically: MolecuLight is a vital asset in modern wound care.' This detailed systematic review of current evidence underscores the capability of MolecuLight devices to identify clinically significant levels of bioburden. This bioburden, frequently undetectable via visual inspection and present in over 80% of chronic wounds,2 frequently causes infection and necessitates targeted intervention. By visualizing bacterial fluorescence, clinicians are equipped to: MolecuLight continues to build on a robust foundation of clinical evidence. With over 100 peer-reviewed publications demonstrating the utility and impact of its fluorescence imaging technology, this systematic review powerfully reinforces that managing bacterial burden is essential for effective wound care. It affirms that MolecuLight devices provide an invaluable and proven tool for clinicians to achieve this, by enabling more precise and targeted interventions that hold strong promise for improved healing trajectories and enhanced patient quality of life. The company remains dedicated to advancing wound care through innovative solutions that improve patient lives and reduce healthcare costs. About MolecuLight Corp. MolecuLight Corp. is a privately owned medical imaging company with a global presence that manufactures and commercializes the MolecuLight i:X® and DX™ wound imaging devices. These are the only Class II FDA-cleared point-of-care imaging devices for the real-time detection of elevated bacterial burden in wounds. They also provide accurate digital wound measurement for comprehensive wound management, supported by strong clinical evidence including over 100 peer-reviewed publications. View original content to download multimedia: SOURCE MolecuLight
Yahoo
12-06-2025
- Health
- Yahoo
MolecuLight® Imaging Significantly Improves Outcomes and Cuts Costs for Deep Sternal Wound Infections in Taiwan Study; Signals Expansion into Surgical Applications
PITTSBURGH and TAIPEI, June 12, 2025 /PRNewswire/ - MolecuLight Corp., a global pioneer in point-of-care fluorescence imaging for wound care, and its Taiwanese distributor, Healtdeva Company Ltd., congratulate researchers at Shuang-Ho Hospital in Taipei, Taiwan on their publication of groundbreaking findings using MolecuLight. The clinical study demonstrates the transformative impact of MolecuLight's i:X® device on the management of deep sternal wound infections (DSWI), showcasing significantly improved patient outcomes alongside cost savings and reduced burden on the healthcare system. The pivotal study, titled "Effects of adjuvant hyperbaric oxygen therapy and real-time fluorescent imaging on deep sternal wound infection: a retrospective study," published in the Journal of Wound Care (2025), revealed that incorporating MolecuLight's real-time fluorescence imaging into the treatment protocol for DSWI led to faster infection resolution, a dramatic reduction in antibiotic use and associated costs, shorter and less intensive hospital stays, and significantly lower rates of dangerous complications like reinfection and osteomyelitis compared to the standard of care with hyperbaric oxygen therapy (HBOT). Key findings that underscore the power of MolecuLight imaging: Significantly Improved Infection Control: MolecuLight-guided treatment increased the likelihood of white blood cell counts returning to normal within 7 days by 26-fold (72.7% vs. 9.1%) and C-reactive protein levels normalizing within 14 days by 7-fold (78.8% vs. 31.8%) compared to HBOT. Reduced Antibiotic Use and Costs: The MolecuLight group required antibiotics for a significantly shorter duration (22 days vs. 29.5 days), leading to nearly two-thirds lower antibiotic costs ($573.57 USD vs. $1643.78 USD). Faster Healing and Reduced Burden on Healthcare Systems: Patients treated with MolecuLight experienced ICU stays that were 70% shorter (3 days vs. 10 days) and achieved complete wound healing 20% faster (40 days vs. 50 days). Significantly Lower Risk of Complications: The use of MolecuLight imaging was associated with an 82% lower likelihood of in-hospital wound reinfection and an 86% lower risk of recurrent osteomyelitis, critical factors in long-term patient well-being and reduced healthcare expenditure. Enhanced Debridement Efficacy: The study highlights MolecuLight's ability to guide more precise and effective debridement, a cornerstone of successful wound management and infection control. "This study demonstrates that MolecuLight delivers tangible benefits in clinical wound management and also serves as a valuable teaching tool in our daily practice. The ability to visualize bacterial presence in real time allows us to more effectively guide younger physicians in understanding critical principles of infection control and intraoperative wound assessment. Moving forward, we intend to continue using this technology to enhance clinical decision-making and overall patient care," said study author Dr. Shun-Cheng Chang, from Shuang-Ho Hospital. "We are honored to introduce MolecuLight's advanced real-time fluorescence imaging technology to Taiwan," remarked Wei-Pin Hsieh, CEO of Healtdeva Company Ltd. "This innovation provides clinicians with a more efficient and accurate tool for assessing infections, opening new diagnostic perspectives in the management of complex wounds and post-operative care. We firmly believe that this technology will have a profound impact on improving patient outcomes and reducing overall healthcare costs." This study underscores the growing recognition of MolecuLight's significant utility beyond chronic wound care and its increasing adoption in critical surgical applications. The company's advanced imaging system, with its unique ability to visualize bacterial presence in real-time and guide targeted interventions, is gaining traction among surgeons looking to optimize outcomes and better manage post-operative complications in various surgical procedures, including the management of deep sternal wound infections (DSWI). "We wish to commend the researchers for their excellent work on this study," said Anil Amlani, CEO of MolecuLight. "These compelling results further validate the significant clinical and economic value of MolecuLight's technology, not only in chronic wound care but also in critical surgical applications. This study, along with our growing adoption in surgical settings, reflects the increasing recognition of our ability to provide critical, real-time information that empowers clinicians to make better decisions at the point of care, ultimately improving patient outcomes and reducing the burden of post-operative complications. We are proud to partner with Healtdeva Company to bring these benefits to patients in Taiwan." About MolecuLight Corp. is a privately owned medical imaging company with a global presence that manufactures and commercializes the MolecuLight i:X® and DX™ wound imaging devices. These are the only class II FDA-cleared point-of-care imaging devices for the real-time detection of elevated bacterial burden in wounds. They also provide accurate digital wound measurement for comprehensive wound management, supported by strong clinical evidence including over 100 peer-reviewed publications. About Healtdeva Company Company Ltd. was established in 1992 and is based in Taipei, Taiwan. Healtdeva Company Ltd. is a trusted distributor of medical technologies and healthcare solutions, with a well-established network across hospitals, clinics, and retail pharmaceuticals, advanced wound care, infection control, and preventive health. Healtdeva Company partners with global innovators to bring cutting-edge medical solutions to the Taiwanese market, driving clinical adoption and commercial success through localized expertise and strategic channel integration. View original content to download multimedia: SOURCE MolecuLight Corp.
Yahoo
12-06-2025
- Health
- Yahoo
MolecuLight® Imaging Significantly Improves Outcomes and Cuts Costs for Deep Sternal Wound Infections in Taiwan Study; Signals Expansion into Surgical Applications
PITTSBURGH and TAIPEI, June 12, 2025 /PRNewswire/ - MolecuLight Corp., a global pioneer in point-of-care fluorescence imaging for wound care, and its Taiwanese distributor, Healtdeva Company Ltd., congratulate researchers at Shuang-Ho Hospital in Taipei, Taiwan on their publication of groundbreaking findings using MolecuLight. The clinical study demonstrates the transformative impact of MolecuLight's i:X® device on the management of deep sternal wound infections (DSWI), showcasing significantly improved patient outcomes alongside cost savings and reduced burden on the healthcare system. The pivotal study, titled "Effects of adjuvant hyperbaric oxygen therapy and real-time fluorescent imaging on deep sternal wound infection: a retrospective study," published in the Journal of Wound Care (2025), revealed that incorporating MolecuLight's real-time fluorescence imaging into the treatment protocol for DSWI led to faster infection resolution, a dramatic reduction in antibiotic use and associated costs, shorter and less intensive hospital stays, and significantly lower rates of dangerous complications like reinfection and osteomyelitis compared to the standard of care with hyperbaric oxygen therapy (HBOT). Key findings that underscore the power of MolecuLight imaging: Significantly Improved Infection Control: MolecuLight-guided treatment increased the likelihood of white blood cell counts returning to normal within 7 days by 26-fold (72.7% vs. 9.1%) and C-reactive protein levels normalizing within 14 days by 7-fold (78.8% vs. 31.8%) compared to HBOT. Reduced Antibiotic Use and Costs: The MolecuLight group required antibiotics for a significantly shorter duration (22 days vs. 29.5 days), leading to nearly two-thirds lower antibiotic costs ($573.57 USD vs. $1643.78 USD). Faster Healing and Reduced Burden on Healthcare Systems: Patients treated with MolecuLight experienced ICU stays that were 70% shorter (3 days vs. 10 days) and achieved complete wound healing 20% faster (40 days vs. 50 days). Significantly Lower Risk of Complications: The use of MolecuLight imaging was associated with an 82% lower likelihood of in-hospital wound reinfection and an 86% lower risk of recurrent osteomyelitis, critical factors in long-term patient well-being and reduced healthcare expenditure. Enhanced Debridement Efficacy: The study highlights MolecuLight's ability to guide more precise and effective debridement, a cornerstone of successful wound management and infection control. "This study demonstrates that MolecuLight delivers tangible benefits in clinical wound management and also serves as a valuable teaching tool in our daily practice. The ability to visualize bacterial presence in real time allows us to more effectively guide younger physicians in understanding critical principles of infection control and intraoperative wound assessment. Moving forward, we intend to continue using this technology to enhance clinical decision-making and overall patient care," said study author Dr. Shun-Cheng Chang, from Shuang-Ho Hospital. "We are honored to introduce MolecuLight's advanced real-time fluorescence imaging technology to Taiwan," remarked Wei-Pin Hsieh, CEO of Healtdeva Company Ltd. "This innovation provides clinicians with a more efficient and accurate tool for assessing infections, opening new diagnostic perspectives in the management of complex wounds and post-operative care. We firmly believe that this technology will have a profound impact on improving patient outcomes and reducing overall healthcare costs." This study underscores the growing recognition of MolecuLight's significant utility beyond chronic wound care and its increasing adoption in critical surgical applications. The company's advanced imaging system, with its unique ability to visualize bacterial presence in real-time and guide targeted interventions, is gaining traction among surgeons looking to optimize outcomes and better manage post-operative complications in various surgical procedures, including the management of deep sternal wound infections (DSWI). "We wish to commend the researchers for their excellent work on this study," said Anil Amlani, CEO of MolecuLight. "These compelling results further validate the significant clinical and economic value of MolecuLight's technology, not only in chronic wound care but also in critical surgical applications. This study, along with our growing adoption in surgical settings, reflects the increasing recognition of our ability to provide critical, real-time information that empowers clinicians to make better decisions at the point of care, ultimately improving patient outcomes and reducing the burden of post-operative complications. We are proud to partner with Healtdeva Company to bring these benefits to patients in Taiwan." About MolecuLight Corp. is a privately owned medical imaging company with a global presence that manufactures and commercializes the MolecuLight i:X® and DX™ wound imaging devices. These are the only class II FDA-cleared point-of-care imaging devices for the real-time detection of elevated bacterial burden in wounds. They also provide accurate digital wound measurement for comprehensive wound management, supported by strong clinical evidence including over 100 peer-reviewed publications. About Healtdeva Company Company Ltd. was established in 1992 and is based in Taipei, Taiwan. Healtdeva Company Ltd. is a trusted distributor of medical technologies and healthcare solutions, with a well-established network across hospitals, clinics, and retail pharmaceuticals, advanced wound care, infection control, and preventive health. Healtdeva Company partners with global innovators to bring cutting-edge medical solutions to the Taiwanese market, driving clinical adoption and commercial success through localized expertise and strategic channel integration. View original content to download multimedia: SOURCE MolecuLight Corp. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
04-06-2025
- Business
- Yahoo
MolecuLight to Showcase Innovative Wound Imaging Platform at the Society for Vascular Surgery Vascular Annual Meeting (VAM) 2025
PITTSBURGH, June 4, 2025 /PRNewswire/ - MolecuLight Corp., a global pioneer in point-of-care fluorescence imaging for rapid detection of infection causing bacteria in wounds, is pleased to announce its participation in the Society for Vascular Surgery (SVS) Vascular Annual Meeting (VAM), taking place in New Orleans, LA, from June 4-7, 2025. MolecuLight will be exhibiting at Booth #654, showcasing its DX™ device that provides clinicians with real-time insights into wound characteristics, including bacterial presence, digital wound measurement, and recently released thermal imaging to visualize temperature changes. The SVS Vascular Annual Meeting is a premier global event for vascular surgeons and healthcare professionals dedicated to advancing the field of vascular health. MolecuLight's technology aligns with this mission by offering objective, evidence-based data that empowers clinicians to make more informed decisions at the point-of-care for improved patient care and outcomes1,2. In addition to its presence on the exhibition floor, MolecuLight is proud to highlight that Dr. Alisha Oropallo has received the Society for Vascular Surgery Section on Ambulatory Vascular Care (SAVC) Presentation Award for her abstract titled, "An objective comparative study of non-surgical cleansing techniques and cleanser types in bacterial burden management." Dr. Oropallo will be presenting her award-winning research during the VAM SAVC session on Friday, June 6th. This study emphasizes the importance of objective assessment in wound care and aligns with MolecuLight's commitment to providing clinicians with the tools they need for effective bacterial burden management. "We are excited to participate in the SVS Vascular Annual Meeting and connect with leading vascular surgeons," said Anil Amlani, CEO of MolecuLight. "We congratulate Dr. Oropallo on this well-deserved recognition and are proud that her research, highlighting the critical need for objective data in wound care, will be presented at this prestigious meeting." Attendees of the SVS Vascular Annual Meeting are invited to visit MolecuLight at Booth #654 to learn more about their DX device and how MolecuLight's innovative wound imaging platform can elevate efficiency in their clinical practice. About the Society for Vascular Surgery (SVS) Vascular Annual Meeting:The Society for Vascular Surgery (SVS) Vascular Annual Meeting (VAM) is the premier international forum for vascular surgeons and other healthcare professionals dedicated to the science, diagnosis, and treatment of vascular disease. This annual event brings together leading experts from around the globe to share the latest research, advancements, and best practices in vascular care. VAM provides a comprehensive educational experience through scientific sessions, interactive workshops, and networking opportunities, all aimed at improving patient outcomes and advancing the field of vascular surgery. About MolecuLight Corp:MolecuLight Corp. is a privately owned medical imaging company with a global presence that manufactures and commercializes the MolecuLight i:X® and DX™ wound imaging devices. These are the only class II FDA-cleared point-of-care imaging devices for the real-time detection of elevated bacterial burden in wounds. They also provide accurate digital wound measurement for comprehensive wound management, supported by strong clinical evidence including over 100 peer-reviewed publications. 1 Jacob A, Jones LM, Abdo RJ, et al. Lights, fluorescence, action-Influencing wound treatment plans including debridement of bacteria and biofilms. Int Wound J. 2023 Oct;20(8):3279-3288. 2 Rahma S, Woods J, Brown S, et al. The Use of Point-of-Care Bacterial Autofluorescence Imaging in the Management of Diabetic Foot Ulcers: A Pilot Randomized Controlled Trial. Diabetes Care. 2022 Jul 7;45(7):1601-1609. View original content to download multimedia: SOURCE MolecuLight Corp.
